ams OSRAM has introduced a multi-chip LED that integrates three wavelengths used for measuring biosignals into a single small package. By incorporating not only traditional biomarkers such as heart rate but also the light source required for long-term measurement of Advanced Glycation End Products (AGEs) into a single component, the product is designed for analyzing long-term health trends.

ams OSRAM (Korea Representative Shim Han-seop) announced on the 22nd that it is launching the multi-chip LED 'SFH 7019'.

In addition to the light sources required for conventional measurements such as heart rate measurement and photoplethysmography (PPG), this product also incorporates a light source necessary for non-invasively evaluating AGE accumulation in tissues through skin autofluorescence (SAF).

The SFH 7019 integrates UV-A light (approx. 383 nm), green light (approx. 530 nm), and infrared light (approx. 980 nm) in a size of 1.65 mm × 2.15 mm × 0.6 mm.

UV-A light stimulates autofluorescence in skin tissue, green light is used for heart rate monitoring and reflection correction, and infrared light is used for PPG.

Each chip can be individually controlled, allowing for the selective application of measurement methods over time. It is possible.

The dedicated photodiode SFH 2705U used in conjunction detects autofluorescence signals and PPG signals simultaneously.

The company explained that the built-in filter blocks UV excitation light while detecting visible and infrared signals, allowing multiple optical measurements to be performed within a single system with minimal mutual interference.

AGEs are generated during metabolic processes and accumulate in collagen-rich skin tissues over a long period, emitting measurable fluorescent signals when subjected to specific light stimulation.

It changes gradually rather than rapidly like heart rate or blood flow, reflecting a continuous physiological burden.

Medical research has reported that high AGE levels are associated with metabolic and vascular stress, such as diabetes, impaired kidney function, and cardiovascular disease.

"Existing biomarkers remain an important foundation for health monitoring," said Stephan Haslbeck, Product Manager at ams OSRAM. "Adding additional indicators allows us to go beyond fragmentary measurements and understand long-term accumulated physiological burdens."

The company stated that this technology can be utilized in the fields of wearables, home care, and prevention-focused healthcare.